(Dapagliflozin + metformin hydrochloride) is under clinical development by Chong Kun Dang Pharmaceutical and currently in Phase I for Type 2 Diabetes. According to GlobalData, Phase I drugs for Type 2 Diabetes have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Dapagliflozin + metformin hydrochloride)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Dapagliflozin + metformin hydrochloride) overview

CKD-387 a fixed dose combination of dapagliflozin and metformin hydrochloride is under development for the treatment of type 2 diabetes. The drug candidate is formulated as tablet and administered through oral route. The drug candidate acts by targeting AMPK and SGLT2.

Chong Kun Dang Pharmaceutical overview

Chong Kun Dang Pharmaceutical (CKD Pharma), an affiliate of Chong Kun Dang, manufactures, distributes, imports and exports prescription drugs, OTC drugs, health supplements and consumer health products. The company works following therapeutic areas such as oncology, neurology and immunology and others. Its product portfolio includes prescription products for the entire segment and therapeutic classes; vitamins; shampoos; hair colors; aerosols; mat vaporizers and mosquito coils; and others. The company’s Chong Kun Dang Research Institute is characterized by three independent laboratories, namely, The New Drug Discovery Labs; The Technology Development Labs; and the Bio Research Labs. It has manufacturing facility in Cheonan City, South Korea. CKD Pharma is headquartered in Seoul, South Korea.

For a complete picture of (Dapagliflozin + metformin hydrochloride)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 15 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.